Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BNR002
MIFTS: 48

Bone Resorption Disease

Categories: Bone diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Bone Resorption Disease

About this section

MalaCards integrated aliases for Bone Resorption Disease:

Name: Bone Resorption Disease 12 15
Bone Resorption 43

Classifications:

MalaCards categories:
Anatomical: Bone diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0080011
MeSH 43 D001862
Sources

Summaries for Bone Resorption Disease

About this section
Disease Ontology : 12 A bone remodeling disease that results in an abnormal decrease of bone density or mass.

MalaCards based summary : Bone Resorption Disease, also known as bone resorption, is related to osteopetrosis and pycnodysostosis. An important gene associated with Bone Resorption Disease is BGLAP (Bone Gamma-Carboxyglutamate Protein), and among its related pathways/superpathways are MicroRNAs in cancer and RANK Signaling in Osteoclasts. The drugs sodium fluoride and Estradiol have been mentioned in the context of this disorder. Affiliated tissues include bone, breast and bone marrow, and related phenotypes are cellular and craniofacial

Wikipedia : 74 Bone resorption is resorption of bone tissue, that is, the process by which osteoclasts break down the... more...

Sources

Related Diseases for Bone Resorption Disease

About this section

Diseases related to Bone Resorption Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 424)
# Related Disease Score Top Affiliating Genes
1 osteopetrosis 33.4 TNFSF11 TNFRSF11B RUNX2 LRP5 CTSK CALCA
2 pycnodysostosis 33.3 TNFSF11 SOST CTSK ACP5
3 multicentric carpotarsal osteolysis syndrome 33.3 TNFSF11 TNFRSF11B CTSK BGLAP ACP5
4 paget's disease of bone 33.2 TNFSF11 TNFRSF11B SOST PTH CALCA BGLAP
5 bone giant cell tumor 33.2 TNFSF11 TNFRSF11B PTH CTSK CALCA ACP5
6 glucocorticoid-induced osteoporosis 33.1 TNFSF11 TNFRSF11B SOST RUNX2 PTH CALCA
7 paget disease of bone 5, juvenile-onset 32.9 TNFSF11 TNFRSF11B CALCA
8 osteitis fibrosa 32.9 SOST PTH CALCA BGLAP
9 periodontitis 32.3 TNFSF11 TNFRSF11B RUNX2 CTSK BGLAP ACP5
10 osteoporosis 32.0 TNFSF11 TNFRSF11B SP7 SOST RUNX2 PTH
11 hyperparathyroidism 31.8 TNFSF11 TNFRSF11B SOST PTH CALCA BGLAP
12 mammary paget's disease 31.8 TNFSF11 TNFRSF11B PTH ESR1 CTSK CALCA
13 bone remodeling disease 31.7 TNFSF11 TNFRSF11B SP7 SOST RUNX2 PTH
14 secondary hyperparathyroidism 31.6 TNFRSF11B PTH CALCA BGLAP ACP5
15 osteoarthritis 31.6 TNFSF11 TNFRSF11B RUNX2 BMP2 BGLAP
16 osteogenic sarcoma 31.6 TNFSF11 TNFRSF11B SP7 RUNX2 PTH MIR140
17 primary hyperparathyroidism 31.5 TNFSF11 TNFRSF11B SOST PTH CALCA BGLAP
18 rheumatoid arthritis 31.5 TNFSF11 TNFRSF11B PTH CTSK BGLAP ACP5
19 hyperthyroidism 31.4 PTH CALCA BGLAP ACP5
20 periodontitis, chronic 31.4 TNFSF11 TNFRSF11B
21 benign giant cell tumor 31.4 TNFSF11 TNFRSF11B CTSK CALCA BGLAP ACP5
22 synovitis 31.4 TNFSF11 TNFRSF11B ACP5
23 osteomalacia 31.4 TNFSF11 SOST PTH CALCA BGLAP
24 myeloma, multiple 31.4 TNFSF11 TNFRSF11B SOST RUNX2 PTH MIR335
25 hypercalcemia, infantile, 1 31.3 PTH CALCA
26 osteonecrosis 31.3 TNFSF11 TNFRSF11B RUNX2 PTH NFATC1 LRP5
27 root resorption 31.3 TNFSF11 TNFRSF11B RUNX2 CTSK CALCA
28 renal osteodystrophy 31.2 TNFSF11 TNFRSF11B SOST PTH CALCA BGLAP
29 osteomyelitis 31.2 TNFSF11 NFATC1 CTSK CALCA BMP2 ACP5
30 rickets 31.1 PTH CALCA BGLAP
31 ankylosis 31.1 TNFSF11 TNFRSF11B SP7 RUNX2 BMP2 BGLAP
32 spondyloarthropathy 1 31.1 TNFSF11 TNFRSF11B PTH BGLAP
33 periapical periodontitis 31.1 TNFSF11 TNFRSF11B CTSK ACP5
34 hypoparathyroidism 31.1 PTH CALCA BGLAP
35 exostosis 31.1 CALCA BMP2 BGLAP
36 hemiplegia 31.0 CALCA BGLAP ACP5
37 hypervitaminosis d 30.9 PTH CALCA
38 endosteal hyperostosis, autosomal dominant 30.9 TNFSF11 TNFRSF11B SP7 SOST NFATC1 LRP5
39 bone inflammation disease 30.8 TNFSF11 TNFRSF11B MIR140
40 bone cancer 30.8 TNFSF11 TNFRSF11B PTH MIR335 MIR140 ESR1
41 sclerosteosis 30.8 TNFSF11 TNFRSF11B SP7 SOST RUNX2 PTH
42 chronic kidney disease 30.8 TNFSF11 TNFRSF11B SOST RUNX2 PTH BGLAP
43 hemophilic arthropathy 30.8 TNFSF11 TNFRSF11B
44 brittle bone disorder 30.8 TNFSF11 TNFRSF11B SP7 SOST RUNX2 PTH
45 scoliosis 30.7 TNFSF11 TNFRSF11B RUNX2 ESR1 CTSK BGLAP
46 osteopetrosis, autosomal recessive 2 30.7 TNFSF11 NFATC1 CTSK ACP5
47 fibrous dysplasia 30.7 TNFSF11 TNFRSF11B RUNX2 CALCA BGLAP
48 hyperphosphatemia 30.7 TNFRSF11B RUNX2 PTH BMP2 BGLAP
49 multicentric reticulohistiocytosis 30.6 TNFSF11 TNFRSF11B
50 camurati-engelmann disease 30.6 SP7 SOST RUNX2 LRP5 BGLAP ACP5

Graphical network of the top 20 diseases related to Bone Resorption Disease:



Diseases related to Bone Resorption Disease
Sources

Symptoms & Phenotypes for Bone Resorption Disease

About this section

MGI Mouse Phenotypes related to Bone Resorption Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10 BGLAP BMP2 CTSK ESR1 LRP5 NFATC1
2 craniofacial MP:0005382 9.76 BMP2 CTSK LRP5 NFATC1 PTH RUNX2
3 limbs/digits/tail MP:0005371 9.7 BMP2 CTSK ESR1 LRP5 NFATC1 PTH
4 skeleton MP:0005390 9.4 BGLAP BMP2 CTSK ESR1 LRP5 NFATC1
Sources

Drugs & Therapeutics for Bone Resorption Disease

About this section

Drugs for Bone Resorption Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 336)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 sodium fluoride Approved Phase 4 7681-49-4
2
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
3
Polyestradiol phosphate Approved Phase 4 28014-46-2
4
Pamidronate Approved Phase 4 40391-99-9 4674
5
Atorvastatin Approved Phase 4 134523-00-5 60823
6
Lovastatin Approved, Investigational Phase 4 75330-75-5 53232
7
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
8
Liraglutide Approved Phase 4 204656-20-2 44147092
9
Curcumin Approved, Experimental, Investigational Phase 4 458-37-7 969516
10
Simvastatin Approved Phase 4 79902-63-9 54454
11
Turmeric Approved, Experimental, Investigational Phase 4
12
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
13
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
14
Potassium citrate Approved, Investigational, Vet_approved Phase 4 866-84-2
15
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850
16
Sodium citrate Approved, Investigational Phase 4 68-04-2
17
Cinacalcet Approved Phase 4 226256-56-0 156419
18
Salmon calcitonin Approved, Investigational Phase 4 47931-85-1 16129616
19
Denosumab Approved Phase 4 615258-40-7
20
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
21
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
22
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
23
Clobetasol Approved, Experimental, Investigational Phase 4 25122-41-2, 25122-46-7 32798 5311051
24
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
25
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
26
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
27
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
28
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
29
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
30
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
31
Calcitonin gene-related peptide Investigational Phase 4 83652-28-2
32
gastric inhibitory polypeptide Investigational Phase 4 100040-31-1
33 Listerine Phase 4
34 calcium channel blockers Phase 4
35 Ibandronic Acid Phase 4
36 Antirheumatic Agents Phase 4
37 Estrogen Antagonists Phase 4
38 Estrogen Receptor Antagonists Phase 4
39 Estrogen Receptor Modulators Phase 4
40 Raloxifene Hydrochloride Phase 4
41 Estradiol 17 beta-cypionate Phase 4
42 Contraceptive Agents Phase 4
43 Estradiol 3-benzoate Phase 4
44 Anti-Retroviral Agents Phase 4
45 Respiratory System Agents Phase 4
46 Ergocalciferols Phase 4
47 Vitamin D2 Phase 4
48 Insulin, Globin Zinc Phase 4
49 Dihydromevinolin Phase 4
50 Hypolipidemic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 510)
# Name Status NCT ID Phase Drugs
1 Bone Resorption, Osteoclastogenesis and Adalimumab Unknown status NCT02035800 Phase 4 Adalimumab
2 Prospective, Non-Randomised, Non-Comparative Multicentric Investigation of the Functional and Radiological Result and Subjective Patient Outcome After Implantation of a Hip Resurfacing Endoprosthesis (Birmingham Hip Resurfacing) Unknown status NCT00180206 Phase 4
3 Clinical and Microbiological Effects of an Essential Oils Solution Used as an Adjunct to Daily Oral Hygiene Practices in Chronic Periodontitis Patients in Supportive Care Unknown status NCT01195493 Phase 4
4 Effects of Sitagliptin On Markers of Bone Turnover in Patients With Type 2 Diabetes Unknown status NCT00732121 Phase 4 Sitagliptin;Placebo
5 Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption Completed NCT01750086 Phase 4 Teriparatide 40-mcg subcutaneous injection;Denosumab Injection;Alendronate Oral Tablet
6 Evaluation of Anterior Alveolar Ridge Reconstruction With Allogenic Bone Plate and Autogenous Cortical Bone Chips: A Radiographic and Histological Clinical Study Completed NCT04324697 Phase 4
7 The Efficacy of Denosumab in Decreasing Periprosthetic Bone Loss in Patients With Total Knee Arthroplasty: A Randomised, Double Blind, Placebo Controlled Clinical Trial Completed NCT02760979 Phase 4 Denosumab;Placebo
8 Periprosthetic Bone Mineral Changes Around Stemless and Stemmed Cementless Femoral Components Completed NCT00957970 Phase 4
9 A Randomized, Double-blind, Placebo-controlled Study to Determine Time to Onset of Suppression of the Bone Resorption Marker sCTX With Once Monthly Ibandronate in the Treatment of Postmenopausal Osteoporosis Completed NCT00303485 Phase 4 Placebo;Vitamin D and calcium supplementation;ibandronate [Bonviva/Boniva]
10 An Open, Prospective, Multi-center Study to Evaluate Bone Loss, the Survival Rate of SPI Implant System and Implant Stability Over a 24 Months, in Patients With Tooth Loss Requiring up to 4 Implants, in Staged Loading Protocol. Completed NCT02367261 Phase 4
11 A Multi-center Study to Evaluate Bone Loss, Survival Rate and Stability of ICE Implant System Over 24 Months, for Patients With Tooth Loss Requiring up to 4 Implants, in Staged Loading Protocol Completed NCT01960361 Phase 4
12 Impact of NTx Point of Care (POC) Device on Patient Satisfication With Actonel 35mg Once a Seek Treatment a Multicenter Prospective Open Label Randomized Controlled Community Practice-based Study Completed NCT00549068 Phase 4 Risedronate Sodium (Actonel)
13 Short-Term Menatetrenone Therapy Increases Gamma-Carboxylation Of Osteocalcin With A Moderate Increase Of Bone Turnover In Postmenopausal Osteoporosis: A Randomized Prospective Study Completed NCT00548509 Phase 4 Menatetrenone (Vitamin K2)
14 Efficacy and Safety of Alendronate in Chinese Children or Adolescents With Osteogenesis Imperfecta: an Age Stratified Prospective Study Completed NCT02303873 Phase 4 Alendronate
15 Enhancing Osteoporosis Therapy: Can We Open the Anabolic Window? Completed NCT01166958 Phase 4 Teriparatide;Raloxifene
16 The Change of Bone Markers After Low Dose Alendronate in Postmenopausal Women Completed NCT00460057 Phase 4 Alendronate
17 The Effect of Vitamin K Supplementation on Bone Health Indices in Adult Crohn's Disease Completed NCT01235325 Phase 4
18 Investigation of the Effects of Bisphosphonate on the Gingival Crevicular Fluid Levels of Sclerostin and the DKK-1 in Individuals With Postmenopausal Osteoporosis With Periodontal Changes Completed NCT04149405 Phase 4 bisphosphonate therapy
19 Effects of 1% Sodium Alendronate in Non Surgical Periodontal Therapy on Clinical and Tomographical Parameters: a Randomized Placebo Controlled 6-month Clinical Trial Completed NCT02470611 Phase 4 Sodium alendronate
20 Do Aromatase Inhibitors (AIs) Decrease Intestinal Calcium Absorption? Completed NCT00766532 Phase 4 Aromatase Inhibitor
21 Denosumab Counteracts Metabolic Bone Disease in Chronic Intestinal Failure Patients: A Randomized, Controlled Clinical Trial Completed NCT02853539 Phase 4 Denosumab
22 Effects of Rosiglitazone on Bone in Postmenopausal Diabetic Women Completed NCT00440375 Phase 4 Rosiglitazone
23 Phase IV Study Teriparatide and Antiresorptive Combination Treatment Subsequent to 9 Months of Teriparatide Monotherapy Completed NCT01535027 Phase 4 teriparatide;teriparatide and raloxifene;teriparatide and alendronate
24 "Comparative Evaluation Of The Efficacy Of Atorvastatin Gel As An Adjunct To Allografts In The Treatment Of Intrabony Defects" - A Clinico Radiological Study Completed NCT03009097 Phase 4 DFDBA with atorvastatin
25 Socket Augmentation Using Atorvastatin With Or Without PRGF Derived Fibrin Scaffold (Clinical and Histomorphometric Study) Completed NCT03228771 Phase 4 PRGF/ATV;ATV gel
26 The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function Completed NCT02473809 Phase 4 Liraglutide;Placebo
27 Curcumin-Simvastatin Release Profile in the Gingival Crevicular Fluid Following EDTA Root Surface Etching in the Surgical Treatment of Intrabony Periodontal Defects - A Biochemical and Clinical Study Completed NCT04044417 Phase 4 curcumin simvastatin paste;EDTA root conditioning
28 A Randomized, Double-Blind, Placebo-Controlled Study of N-3 Fatty Acid on Plasma Triglyceride Levels in Hypertriglyceridemic HIV Patients Receiving Highly Active Antiretroviral Therapy Completed NCT00346697 Phase 4 Omega-3 fatty acid administration;Placebo
29 Osteopenia and Renal Osteodystrophy: Evaluation and Management Completed NCT00108394 Phase 4 pamidronate
30 Local Minocycline to Reduce Future Inflammation and Bone Loss in Periodontal Maintenance Patients Completed NCT01647282 Phase 4 locally-applied minocycline HCl (1 mg)
31 Socket Augmentation Using Different Platelet Concentrates, Atorvastatin Gel or Combination (Clinical and Histomorphometric Study) Completed NCT03231137 Phase 4 ATV gel
32 The Study of Efficacy and Safety of Calcium Sensing Receptor in Chronic Dialysis Patients Completed NCT02056730 Phase 4 calcium sensing receptor agonist
33 Estrogen Dosing in Turner Syndrome:Pharmacology & Metabolism Completed NCT00837616 Phase 4 17 B estradiol orally;17 B estradiol
34 A Randomized Placebo Controlled Double Blind Investigation of the Effects of Potassium Citrate on Bone Metabolism in Postmenopausal Osteopenia Completed NCT00357331 Phase 4 potassium citrate
35 The P.O.W.E.R. STUDY (Premenopause, Osteopenia/Osteoporosis, Women, Alendronate, Depression) Completed NCT00006180 Phase 4 Alendronate
36 The Effect Of The Bisphosphonate, Zoledronic Acid, On Bone Density In Liver Transplant Patients – A Prospective, Randomised, Controlled Clinical Trial Completed NCT00114556 Phase 4 zoledronic acid
37 Denosumab in Primary Hyperparathyroidism Completed NCT01558115 Phase 4 Denosumab
38 Treatment of Vitamin D Insufficiency Completed NCT00933244 Phase 4
39 Estimation of Interleukin-21 Levels in Gingival Crevicular Fluid in Patients With Periodontal Health and Disease Following Non-surgical Periodontal Therapy: A Clinico-biochemical Study Completed NCT02861937 Phase 4
40 Is Dietary Melatonin Supplementation a Viable Adjunctive Therapy for Chronic Periodontitis? A Preliminary Randomized Clinical Trial. Completed NCT03368430 Phase 4 Placebo
41 Clinical, Radiographic and Histologic Evaluation of a Novel Alveolar Ridge Reconstruction Approach in Post-Extraction Dehiscence Defects: A Case Series Study Completed NCT02980211 Phase 4 Alveolar Ridge Reconstruction
42 Platelet Rich Fibrin (PRF) Membranes in Lateral Alveolar Ridge Augmentation. A Randomized Controlled Study Comparing an Autogenous Bone Graft Covered by a Platelet Rich Fibrin (PRF) Membrane (Test Group) or an Anorganic Bovine Bone Substitute and a Resorbable Collagen Barrier Membrane (Control Group) Completed NCT04350749 Phase 4
43 A Method for Measuring Volume Changes of the Alveolar Ridge During Dental Implantation Using 3D Scanning Recruiting NCT03089619 Phase 4 Human-Spongiosa
44 Hyaluronic Acid Effect on Xenogenic Bone Substitutes Healing During Ridge Preservations: A Radiological and Histomorphometric Study Recruiting NCT04377256 Phase 4
45 Department of Orthopedics, National Taiwan University Hospital Recruiting NCT03868033 Phase 4 Zoledronic Acid;Denosumab
46 Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery Recruiting NCT04087096 Phase 4 Denosumab;Placebo;Zoledronic Acid
47 The Use of Intranasal Calcitonin to Improve Pain and Activity in Elderly Pelvic Ring Injuries Recruiting NCT03812991 Phase 4 Miacalcin Calcitonin Salmon Nasal Spray
48 The Efficacy of Denosumab to Prevent Bone Loss in Ambulatory and Non-ambulatory Motor-Incomplete Patients With Subacute Spinal Cord Injury Recruiting NCT03029442 Phase 4 Denosumab (Prolia)
49 Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism Recruiting NCT03887936 Phase 4 Testosterone gel 1.62%;Placebo
50 Novel Combination Therapy for Osteoporosis in Men Recruiting NCT03994172 Phase 4 Teriparatide or human parathyroid hormone (PTH) 1-34;Cinacalcet;placebo tablet

Search NIH Clinical Center for Bone Resorption Disease

Cochrane evidence based reviews: bone resorption

Sources

Genetic Tests for Bone Resorption Disease

About this section
Sources

Anatomical Context for Bone Resorption Disease

About this section

MalaCards organs/tissues related to Bone Resorption Disease:

40
Bone, Breast, Bone Marrow, Prostate, Monocytes, T Cells, Kidney
Sources

Publications for Bone Resorption Disease

About this section

Articles related to Bone Resorption Disease:

(show top 50) (show all 24949)
# Title Authors PMID Year
1
Histologic evaluation of femoral nerve demyelinating and axonal neuropathy in Wistar rats due to alendronate intake: a randomised study. 61
32099834 2020
2
Romosozumab was not effective in preventing multiple spontaneous clinical vertebral fractures after denosumab discontinuation: A case report. 61
32548215 2020
3
Ellagic acid protects ovariectomy-induced bone loss in mice by inhibiting osteoclast differentiation and bone resorption. 61
32026468 2020
4
Associations between the serum levels of selected bone turnover markers and biological traits in nursing home women aged 80+ without inflammation. A pilot study. 61
32428562 2020
5
Bone and Mineral Metabolism in Children with Nephropathic Cystinosis Compared with other CKD Entities. 61
32413117 2020
6
Ionizing Radiation Exacerbates the Bone Loss Induced by Iron Overload in Mice. 61
31691189 2020
7
Bisphosphonates inhibit surface-mediated osteogenesis. 61
32276287 2020
8
Diaporisoindole E inhibits RANKL-induced osteoclastogenesis via suppression of PI3K/AKT and MAPK signal pathways. 61
32510335 2020
9
GSH attenuates RANKL-induced osteoclast formation in vitro and LPS-induced bone loss in vivo. 61
32485573 2020
10
Anti-osteoporotic effects of Salvia miltiorrhiza Bunge EtOH extract both in ovariectomized and naturally menopausal mouse models. 61
32311485 2020
11
Dynamic microstructural changes in alveolar bone in ligature-induced experimental periodontitis. 61
31713702 2020
12
Effect of stress-shielding-induced bone resorption on glenoid loosening in reverse total shoulder arthroplasty. 61
32374418 2020
13
Possible roles of parathyroid hormone, 1.25(OH)2D3, and fibroblast growth factor 23 on genes controlling calcium metabolism across different tissues of the laying hen. 61
32006872 2020
14
Synthesis and biological activities of drugs for the treatment of osteoporosis. 61
32335412 2020
15
Abeliophyllum distichum Nakai alleviates postmenopausal osteoporosis in ovariectomized rats and prevents RANKL-induced osteoclastogenesis in vitro. 61
32268206 2020
16
Autophagy-dependent mitochondrial function regulates osteoclast differentiation and maturation. 61
32430180 2020
17
Redox injectable gel protects osteoblastic function against oxidative stress and suppresses alveolar bone loss in a rat peri-implantitis model. 61
32348918 2020
18
The biological function of BMAL1 in skeleton development and disorders. 61
32251631 2020
19
On the design and properties of porous femoral stems with adjustable stiffness gradient. 61
32505662 2020
20
Strain shielding for cemented hip implants. 61
32447179 2020
21
C-terminal telopeptide of type I collagen, osteocalcin, alkaline phosphatase, and parathyroid hormone in healthy and hospitalized foals. 61
32408050 2020
22
IL-10 secreting B cells regulate periodontal immune response during periodontitis. 61
31701299 2020
23
Sleep Restriction With Circadian Disruption Negatively Alter Bone Turnover Markers in Women. 61
32364602 2020
24
Bovine Bone Promotes Osseous Protection via Osteoclast Activation. 61
32167856 2020
25
Reactive oxygen/nitrogen species (ROS/RNS) and oxidative stress in arthroplasty. 61
31898397 2020
26
7ND protein exerts inhibitory effects on both osteoclast differentiation in vitro and lipopolysaccharide‑induced bone erosion in vivo. 61
32377737 2020
27
Effects of menopausal state on lumbar decompression and fusion surgery. 61
32387254 2020
28
Dual targeting of SREBP2 and ERRα by carnosic acid suppresses RANKL-mediated osteoclastogenesis and prevents ovariectomy-induced bone loss. 61
31907393 2020
29
Isoalantolactone inhibits RANKL-induced osteoclast formation via multiple signaling pathways. 61
32388216 2020
30
The effect of lipoxin A4 on E. coli LPS-induced osteoclastogenesis. 61
32506323 2020
31
A Pooled Analysis of Fall Incidence From Placebo-Controlled Trials of Denosumab. 61
31999376 2020
32
Regular supplementation with resveratrol improves bone mineral density in postmenopausal women: a randomised, placebo-controlled trial. 61
32564438 2020
33
Osteoclast formation at the bone marrow/bone surface interface: Importance of structural elements, matrix, and intercellular communication. 61
32563679 2020
34
Osteoclasts and their circulating precursors in rheumatoid arthritis: Relationships with disease activity and bone erosions. 61
32478145 2020
35
[Multidisciplinary treatment of patient with periodontitis and vertical bone resorption of mandibular molars: a case report]. 61
32486572 2020
36
Boldine inhibits the alveolar bone resorption during ligature-induced periodontitis by modulating the Th17/Treg imbalance. 61
32490537 2020
37
Interleukin-35 inhibits alveolar bone resorption by modulating the Th17/Treg imbalance during periodontitis. 61
32160331 2020
38
Glyburide inhibits the bone resorption induced by traumatic occlusion in rats. 61
32153049 2020
39
Osteocyte lacunar strain determination using multiscale finite element analysis. 61
32478144 2020
40
Designing a mandibular advancement device with topology optimization for a partially edentulous patient. 61
31590981 2020
41
Both NPY-Expressing and CART-Expressing Neurons Increase Energy Expenditure and Trabecular Bone Mass in Response to AP1 Antagonism, But Have Opposite Effects on Bone Resorption. 61
31995643 2020
42
Siglec-15-targeting therapy protects against glucocorticoid-induced osteoporosis of growing skeleton in juvenile rats. 61
32217159 2020
43
Correction: Modulated podosome patterning in osteoclasts by fullerenol nanoparticles disturbs the bone resorption for osteoporosis treatment. 61
32478778 2020
44
Bone-Targeting AAV-Mediated Gene Silencing in Osteoclasts for Osteoporosis Therapy. 61
32405514 2020
45
Linking skeletal muscle aging with osteoporosis by lamin A/C deficiency. 61
32479501 2020
46
Protein array test detected three osteoporosis related plasma inflammatory cytokines in Chinese postmenopausal women. 61
32570159 2020
47
Mesenchymal stem cell in mice uterine and its therapeutic effect on osteoporosis. 61
32567490 2020
48
Ovariectomy Activates Chronic Low-Grade Inflammation Mediated by Memory T Cells, Which Promotes Osteoporosis in Mice. 61
31995253 2020
49
Novel gene Merlot inhibits differentiation and promotes apoptosis of osteoclasts. 61
32569872 2020
50
Energy metabolism: A newly emerging target of BMP signaling in bone homeostasis. 61
32512164 2020
Sources

Variations for Bone Resorption Disease

About this section
Sources

Expression for Bone Resorption Disease

About this section
Search GEO for disease gene expression data for Bone Resorption Disease.
Sources

Pathways for Bone Resorption Disease

About this section

Pathways related to Bone Resorption Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
MicroRNAs in cancer 36
12.27 MIR335 MIR23A MIR214 MIR133A1
2
RANK Signaling in Osteoclasts 63
Show member pathways
 12.25 TNFSF11 TNFRSF11B NFATC1 CTSK ACP5
3
Osteoclast differentiation 36
11.91 TNFSF11 TNFRSF11B NFATC1 CTSK ACP5
4
Rheumatoid arthritis 36
11.7 TNFSF11 PTH CTSK ACP5
5
Mesenchymal Stem Cells and Lineage-specific Markers 64
11.7 SP7 RUNX2 PTH BMP2 BGLAP
6
Parathyroid hormone synthesis, secretion and action 36
11.46 TNFSF11 SOST RUNX2 PTH LRP5 BGLAP
7
Development_Hedgehog and PTH signaling pathways in bone and cartilage development 22
11.26 TNFSF11 RUNX2 PTH BGLAP
8
Osteoclast Signaling 1
10.76 TNFSF11 TNFRSF11B CTSK ACP5
9
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
10.75 TNFSF11 TNFRSF11B RUNX2 PTH CALCA BGLAP
10
Osteoblast Signaling 1
10.6 TNFSF11 TNFRSF11B PTH BGLAP
Sources

GO Terms for Bone Resorption Disease

About this section

Cellular components related to Bone Resorption Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.4 TNFSF11 TNFRSF11B SOST PTH MIR335 MIR23A

Biological processes related to Bone Resorption Disease according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.97 TNFSF11 SP7 RUNX2 PTH NFATC1 LRP5
2 positive regulation of gene expression GO:0010628 9.95 TNFSF11 RUNX2 MIR140 MIR133A1 BMP2
3 positive regulation of transcription, DNA-templated GO:0045893 9.93 SOST RUNX2 NFATC1 LRP5 ESR1 BMP2
4 gene silencing by miRNA GO:0035195 9.88 MIR335 MIR23A MIR214 MIR188 MIR140 MIR133A1
5 positive regulation of DNA-binding transcription factor activity GO:0051091 9.79 TNFSF11 LRP5 ESR1
6 response to estrogen GO:0043627 9.7 TNFRSF11B ESR1 BGLAP
7 positive regulation of osteoblast differentiation GO:0045669 9.69 RUNX2 LRP5 BMP2
8 bone development GO:0060348 9.67 TNFSF11 LRP5 BGLAP
9 osteoblast differentiation GO:0001649 9.62 SP7 RUNX2 BMP2 BGLAP
10 mammary gland alveolus development GO:0060749 9.61 TNFSF11 ESR1
11 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.61 MIR214 MIR140 MIR133A1
12 response to vitamin D GO:0033280 9.6 PTH BGLAP
13 response to inorganic substance GO:0010035 9.59 TNFRSF11B BGLAP
14 negative regulation of bone resorption GO:0045779 9.58 TNFRSF11B CALCA
15 positive regulation of ossification GO:0045778 9.58 PTH BMP2
16 regulation of osteoclast differentiation GO:0045670 9.57 TNFSF11 BGLAP
17 positive regulation of osteoblast proliferation GO:0033690 9.56 LRP5 BMP2
18 skeletal system development GO:0001501 9.55 TNFRSF11B RUNX2 PTH BMP2 BGLAP
19 positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus GO:1901522 9.54 RUNX2 BMP2
20 regulation of odontogenesis of dentin-containing tooth GO:0042487 9.48 RUNX2 BMP2
21 osteoblast development GO:0002076 9.43 RUNX2 LRP5 BGLAP
22 bone resorption GO:0045453 9.26 TNFSF11 PTH CTSK ACP5
23 ossification GO:0001503 9.1 TNFSF11 SOST RUNX2 BMP2 BGLAP ACP5

Molecular functions related to Bone Resorption Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.02 MIR23A MIR214 MIR188 MIR140 MIR133A1
Sources

Sources for Bone Resorption Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....